论文部分内容阅读
食管癌是我国常见约恶性肿瘤之一,居我国恶性肿瘤死亡率的第二位。一般初诊时,约有50％～60％的病人已属中晚期,失去根治机会。尽管食管癌对抗癌药较不敏感,但近年来临床研究提示有些抗癌药物对食管癌有一定的疗效,1986年1月～1986年12月底,我们采用顺氯氨铂为主的联合方案,即由顺氯氟铂(DDP)、甲氨喋呤(MTX)、平阳霉素(BLM)组成的PMB方案,在门诊治疗30例晚期食管癌病人,现将其中化疗满二个疗程以上的24例分析如下。
Esophageal cancer is one of the common malignant tumors in China, ranking second in the mortality rate of malignant tumors in China. At the time of initial diagnosis, approximately 50% to 60% of patients were already in advanced stages and lost their chances of radical cure. Although esophageal cancer is less sensitive to anticancer drugs, clinical studies in recent years have suggested that some anticancer drugs have a certain effect on esophageal cancer. From January 1986 to the end of December 1986, we used a combination of cisplatin-based solutions. The PMB regimen consists of cis-chlorofluoroplatin (DDP), methotrexate (MTX), and bleomycin (BLM), and 30 patients with advanced esophageal cancer are treated in an outpatient department. Now the chemotherapy is over two cycles. 24 cases were analyzed as follows.